11/13
12:56 pm
crbp
Corbus Pharmaceuticals (NASDAQ:CRBP) had its price target lowered by analysts at Royal Bank Of Canada from $55.00 to $53.00. They now have an "outperform" rating on the stock.
Low
Report
Corbus Pharmaceuticals (NASDAQ:CRBP) had its price target lowered by analysts at Royal Bank Of Canada from $55.00 to $53.00. They now have an "outperform" rating on the stock.
11/12
08:00 am
crbp
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Medium
Report
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
11/6
08:00 am
crbp
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Medium
Report
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
10/31
05:31 pm
crbp
Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window [Seeking Alpha]
Low
Report
Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window [Seeking Alpha]
10/31
02:40 am
crbp
Corbus Pharmaceuticals Announces Pricing of Public Offering
High
Report
Corbus Pharmaceuticals Announces Pricing of Public Offering
10/30
04:31 pm
crbp
Corbus Pharmaceuticals Announces Proposed Public Offering
High
Report
Corbus Pharmaceuticals Announces Proposed Public Offering
10/29
10:07 am
crbp
Corbus Pharmaceuticals (NASDAQ:CRBP) was given a new $39.00 price target on by analysts at Mizuho.
Low
Report
Corbus Pharmaceuticals (NASDAQ:CRBP) was given a new $39.00 price target on by analysts at Mizuho.
10/20
10:17 am
crbp
Corbus Pharmaceuticals (NASDAQ:CRBP) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
High
Report
Corbus Pharmaceuticals (NASDAQ:CRBP) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
10/20
09:23 am
crbp
Corbus Pharmaceuticals (NASDAQ:CRBP) had its price target raised by analysts at Wedbush from $31.00 to $38.00. They now have an "outperform" rating on the stock.
High
Report
Corbus Pharmaceuticals (NASDAQ:CRBP) had its price target raised by analysts at Wedbush from $31.00 to $38.00. They now have an "outperform" rating on the stock.
10/20
08:47 am
crbp
Corbus Pharmaceuticals (NASDAQ:CRBP) had its "reduce" rating reaffirmed by analysts at Benchmark Co..
High
Report
Corbus Pharmaceuticals (NASDAQ:CRBP) had its "reduce" rating reaffirmed by analysts at Benchmark Co..
10/20
08:08 am
crbp
Corbus Pharmaceuticals (NASDAQ:CRBP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
High
Report
Corbus Pharmaceuticals (NASDAQ:CRBP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
10/18
09:03 am
crbp
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 [Yahoo! Finance]
Medium
Report
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 [Yahoo! Finance]
10/18
03:00 am
crbp
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
Medium
Report
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
10/14
08:11 am
crbp
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 [Yahoo! Finance]
Low
Report
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 [Yahoo! Finance]
10/14
08:00 am
crbp
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
Low
Report
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
10/7
08:00 am
crbp
Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium
Low
Report
Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium
9/22
08:43 am
crbp
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025 [Yahoo! Finance]
Low
Report
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025 [Yahoo! Finance]
9/22
08:00 am
crbp
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025
Low
Report
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025
9/17
08:05 am
crbp
Corbus Pharmaceuticals (NASDAQ:CRBP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
High
Report
Corbus Pharmaceuticals (NASDAQ:CRBP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
9/16
08:00 am
crbp
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
Medium
Report
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma